iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Tables)

Significant Transactions (Tables)

9 Months Ended

Mar. 31, 2024

Summary of Purchase Price Allocation of Asset Acquisition


Preferred stock		$	1,760,000
Intangible assets			4,300,000
Prepaid expenses			1,440,000
		$	7,500,000

RubrYc Therapeutics Inc [Member] | Asset Purchase Agreement [Member]

Summary of Purchase Price Allocation of Asset Acquisition


Intangible assets		$	1,228,000
Fixed assets			114,000
		$	1,342,000